Intellia Therapeutics (NTLA-Q)

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

NTLA has $912.2M in total cash and short term investments. Cash and equivalents is $226.7M while $685.5M is in short term investments. Insider ownership is 9.39%. NTLA is expected to be highly unprofitable over the next three years, but revenue is expected grow at 40% this year, then flat in 2025. We think it is a very speculative play and it is also highly unprofitable and burning through cash at a high rate. Share price appreciation will be reliant on bringing NTLA-2001 to market. 
Unlock Premium - Try 5i Free

Biotech is an exciting area to be looking at. It is higher growth but higher risk - along with higher reward. Biotech has under-performed for the past two years. Intellia has used crisper technology to target mutated genes dealing with autoimmune and rare diseases - and try to cure them. They are at third stage trials this year. It has $2 billion cash which is good for two years of R&D. Management is good.      Buy 25  Hold 6  Sell 0

(Analysts’ price target is $69.96)

Announced positive early results in gene-editing that would treat a rare genetic disease that impacts 50,000 people. Shares shot up 50% today. Regeneron is their partner. Cathy Wood heavily invests in these stocks.